Senate Democrats raise questions about RFK Jr. divestment tied to HPV vaccine Gardasil lawsuit

Senate Democrats are questioning whether Health and Human Services Secretary Robert F. Kennedy Jr. complied with divestment requirements tied to a lawsuit involving the HPV vaccine Gardasil, according to a report published Tuesday by The Hill. The lawmakers want to understand whether Kennedy fully separated himself from financial interests related to a case they say he helped initiate before his confirmation as HHS secretary.

The Hill report says the issue centers on a lawsuit connected to the HPV vaccine Gardasil that was led by the law firm Wisner Baum. The report states Kennedy was part of that lawsuit before he assumed his current federal role, raising questions among Democrats about how his financial interests were handled when he became HHS secretary.

At the center of the lawmakers’ questions is whether the divestment Kennedy conducted before or during the confirmation process was sufficient in practical terms, not just on paper. The report describes the inquiry as a test of whether Kennedy truly divested his financial interests in the Gardasil-related matter.

The lawmakers’ scrutiny also highlights a broader theme in confirmation and ethics reviews: whether a Cabinet-level official who previously took part in litigation has taken steps to avoid conflicts of interest once they oversee the agencies with regulatory and enforcement responsibilities in the relevant health sector.

Because the matter involves vaccine-related litigation, the practical implications extend beyond the individuals at issue. The HHS secretary oversees parts of the federal public health and health regulation apparatus that interact with vaccine policy, including how the department approaches medical products, oversight frameworks, and how it responds to public health claims and enforcement priorities.

The report frames the Democrats’ concerns as focused on compliance with divestment expectations rather than a dispute over the underlying vaccine claims themselves. In that sense, the dispute is less about re-litigating the merits and more about whether an official’s financial exposure was appropriately removed before taking office.

Next steps, according to the reporting, are tied to whether Kennedy can provide documentation or specific details that satisfy the questions raised by senators about the timing and effectiveness of the divestment.